| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12913283 | IVTH | 0.000001 - 0.001 M | 0.00005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:15379888 | IVR | 0.000087 mmol | 0.000087 mmol | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.000087 mmol | 0.000087 mmol | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.0000087 mmol | 0.0000087 mmol | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.00000087 mmol | 0.00000087 mmol | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.000000087 mmol | - | No significant effects observed | - | |
| PMID:15620428 | IVR | 0.087 M | 0.087 M | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| IVR | 0.087 M | 0.087 M | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:15883486 | IVTH | 0.000000001 - 0.001 M | 0.000001 - 0.0001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:16641545 | IVR | 6000 mg/L | 6000 mg/L | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 6000 mg/L | 6000 mg/L | Atrophy in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Decreased brain weights in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Decreased thymus gland weights in offspring | Developmental endocrine-mediated perturbations;Immunological endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Decreased spleen weights in offspring | Developmental endocrine-mediated perturbations;Immunological endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 6000 mg/L | 6000 mg/L | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 240 mg/L | 240 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1200 mg/L | 1200 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1200 mg/L | 1200 mg/L | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 1200 mg/L | 1200 mg/L | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations | |
| IVR | 1200 mg/L | 1200 mg/L | Increased androstenedione levels | Reproductive endocrine-mediated p | |
| PMID:19410640 | IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | - | No significant effects observed | - | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:25637754 | IVR | 500 mg/kg/day | 500 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:33983380 | IVR | 9 mg/kg/day | 9 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 1 - 9 mg/kg/day | 1 - 9 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 33 mg/kg/day | 1 - 33 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:34851150 | IVR | 1 mg/kg/day | 1 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
| PMID:36709676 | IVR | 1 mg/kg/day | 1 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations |
| PMID:37274322 | IVR | 5 mg/kg | 5 mg/kg | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased brain weights | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg | 1 - 2 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 2 - 5 mg/kg | 2 - 5 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.